An open label, randomized, two arms trial to evaluate the safety and efficacy of extract of Commiphora myrrha (Myrlimax capsule) in comparison to etoricoxib in patients with arthritis. - NI

VIGNANS FOUNDATION OF SCIENCE, TECHNOLOGY AND RESEARCH0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年7月22日

试验速览

暂无简介。

•1.Diagnosis of arthritis rheumatoid arthritis
•2. osteoarthritis gout arthritis based on history clinical presentation and radiological findings
•3. Minimum VAS 4 on walking in one or both hands or knee during 24 hours preceding requirement
•4. Patient ambulant and requiring treatment for arthritis
•5. Post operative patients are also eligible
•6. Willing to come for regular follow up visits
•7. Able to give written informed consent form

•1. Known history of hypersensitivity to herbal extracts or dietary supplements.
•2. Pregnant women, lactating women and women of childbearing potential not following adequate contraceptive measure, women who were found to positive for urine pregnancy test.
•3. Patient incapacitated or bound to wheelchair or bed and unable to carryout self- care activities.
•4. Treatment with intra- articular injection of corticosteroids into knee within 3 months preceding study.
•5. Pre- existing or recent onset of demyelinating disorders or type I diabetes.
•6. Ongoing treatment with anticoagulants, hydantoin, lithium, steroids, methotrexate and colchicine.
•7. Evidence of serval renal, hepatic or hemopoietic disease or severe cardiac insufficiency as revealed by laboratory investigations.
•8. Patient with congestive heart failure.
•9. Patient with hypertension
•10. Clinically significant untreated hyper-lipidaemia in context of cardiovascular risk
•11. History of having received any investigational drug or participated in any other clinical trial which ended in preceding month or currently ongoing.
•12. Ayurvedic formulation or any form of CAM (complimentary alternative medicine) therapy in the preceding 2 months.
•13. Non- co- operative attitude of patients
•14. Any condition that in the opinion of the investigator does not justify the patient’s inclusion for the study

发起方

VIGNANS FOUNDATION OF SCIENCE, TECHNOLOGY AND RESEARCH